The Soluble Form of the Axl Receptor Tyrosine Kinase

Ekman, Carl

2010

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
The soluble form of the Axl receptor tyrosine kinase

Carl Ekman
Doctoral thesis

Academic dissertation
By due permission of the Faculty of Medicine, Lund University, Sweden to be defended in the Pathology lecture hall, Skåne University Hospital, Friday the 10th of December 2010 at 13.00 for the degree of Doctor of Philosophy, Faculty of Medicine.

Faculty Opponent
Professor Gian Carlo Avanzi
Dipartimento di Medicina Clinica e Sperimentale
Università del Piemonte Arientale A.Avogadro
The present investigation focuses on the receptor Axl, member of the receptor tyrosine kinase family. Axl is activated by the ligand Gas6, which induces cell growth and proliferation, but also regulates inflammation and vascular homeostasis. The Axl receptor can be cleaved outside the membrane, releasing the extracellular, soluble domain, which alone can bind Gas6, removing it from cell-bound receptors.

The first study focused on soluble Axl (sAxl), which was found to be secreted from several human cell lines and to be present in human circulation. An ELISA was developed against Axl to determine the concentration of sAxl. Through immunoprecipitation and gel filtration, Gas6 was found to be in complex with sAxl, with sAxl in molar excess over Gas6.

In the second study, patients with abdominal aortic aneurysms were investigated with Gas6 and sAxl ELISAs. Gas6 was increased and sAxl is decreased compared to the control group. Aneurysm size correlated to Gas6 concentration and inversely to sAxl concentration. The Gas6/sAxl ratio correlated better to Aneurysm size, and 40% of all patients with large Aneurysms had higher Gas6/sAxl ratio than any in the control group.

The third study investigated patients with critical limb ischemia. The patients had high Gas6 and sAxl, and both proteins correlated with several inflammatory markers. Patients with high Gas6 and sAxl had worse prognosis with higher mortality, independent of age and gender.

The fourth study assessed patients with sepsis and related inflammatory conditions. In septic patients, Gas6 was twice the concentration observed in the controls, and sAxl was also increased. Gas6 was especially increased in patients with organ failure, patients demoting intensive care or renal support.

The fifth study focused on patients with systemic lupus erythematosus. Gas6 and sAxl correlated with disease intensity, and was increased in patients with glomerulonephritis and presence of anti-DNA antibodies. Altogether, the results from this thesis indicate that Gas6 is bound to sAxl in circulation and that Gas6 and sAxl are increased in various inflammatory conditions.

Keywords: Gas6, Axl, sAxl, AAA, CLI, SIRS, SLE, TAM, inflammation
The soluble form of the Axl receptor tyrosine kinase

Carl Ekman
Doctoral thesis

Division of Clinical Chemistry
Department of Laboratory Medicine
Faculty of Medicine
Lund University 2010

© Carl Ekman 2010
ISBN 978-91-86671-34-1
ISSN 1652-8220

Erlend Loe
# Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of papers</td>
<td>8</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>9</td>
</tr>
<tr>
<td>Introduction</td>
<td>11</td>
</tr>
<tr>
<td>Background</td>
<td>12</td>
</tr>
<tr>
<td>The present investigation</td>
<td>33</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>53</td>
</tr>
<tr>
<td>References</td>
<td>55</td>
</tr>
<tr>
<td>Appendix</td>
<td>77</td>
</tr>
</tbody>
</table>
List of papers

This thesis is based on the following papers, which are referred to in the text by their Roman numerals:


Paper I is reprinted with permission from Wiley, Paper II and III are with permission from Elsevier and paper IV is with permission from BioMed Central.
**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>Abdominal aorta aneurysm</td>
</tr>
<tr>
<td>APC</td>
<td>activated protein C</td>
</tr>
<tr>
<td>C4BP</td>
<td>C4-binding protein</td>
</tr>
<tr>
<td>CLI</td>
<td>Critical limb ischemia</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>Gas6</td>
<td>Growth arrest specific 6</td>
</tr>
<tr>
<td>Gas6sv</td>
<td>Gas6 splice variant</td>
</tr>
<tr>
<td>Gla</td>
<td>gamma carboxylated glutamic acid</td>
</tr>
<tr>
<td>Ig</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>HUVEC</td>
<td>human umbilical vein endothelial cell</td>
</tr>
<tr>
<td>LG</td>
<td>Laminin G</td>
</tr>
<tr>
<td>Mertk</td>
<td>Mer tyrosine kinase</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>PS</td>
<td>Phosphatidylserine</td>
</tr>
<tr>
<td>RPE</td>
<td>Retinal pigment epithelial cell</td>
</tr>
<tr>
<td>RTK</td>
<td>Receptor tyrosine kinase</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>sAxl</td>
<td>soluble Axl</td>
</tr>
<tr>
<td>SIRS</td>
<td>Systemic inflammatory response syndrome</td>
</tr>
<tr>
<td>SLE</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>sMer</td>
<td>soluble Mer</td>
</tr>
<tr>
<td>SMC</td>
<td>smooth muscle cell</td>
</tr>
<tr>
<td>sTyro3</td>
<td>soluble Tyro3</td>
</tr>
<tr>
<td>TAM</td>
<td>Tyro3, Axl and Mer</td>
</tr>
<tr>
<td>TNFα</td>
<td>Tumor necrosis factor alpha</td>
</tr>
</tbody>
</table>
Cells express multiple receptors to be able to respond to their local microenvironment. These receptors are activated by ligands, which may be proteins, sugars, fats or other molecules. When the ligand binds the receptor, the receptor becomes activated and starts a signalling cascade, which will influence the receptor-bearing cell. One large family of receptors is the enzyme-linked receptors comprising five subfamilies, including receptor tyrosine kinases (RTK). The RTKs have an extracellular domain, one transmembrane domain and one intracellular domain with enzymatic activity. When the ligand binds a RTK, the receptors assemble into dimers, bringing the intracellular domains in close proximity. The intracellular domains will phosphorylate each other at specific tyrosine residues, enabling adaptor proteins to bind to the now activated receptor dimer. The adaptor proteins will transmit the signal into the cell, leading to altered cell behavior.

The human genome encodes 58 receptor tyrosine kinases, which are grouped in 20 families based on homology. The receptors of the TAM family have similar domain organization, with two immunoglobulin domains, two fibronectin domains in the extracellular domain. The TAM family include the Tyro3, Axl and Mer receptors. My thesis will focus on the soluble form of the Axl receptor, but will also give an introduction to the TAM family at large including the ligands Gas6 and protein S.
Background

The *Gas6* gene and the Gas6 protein

The gene coding for growth arrest specific-6 (*Gas6*) was discovered in 1988 when searching for genes specifically expressed in growth-arrested fibroblasts. 6 genes were found and they were named *gas1* to *gas6*. The expression of these genes was high when cells were treated with media low in nutrients, but when the media was changed to a growth factor rich media, the expression decreased. The full-length human cDNA for Gas6 is 2,461 nucleotides long and encodes a 75 kDa protein consisting of 678 amino acids. Gas6 was found to be similar to the vitamin K-dependent protein S, sharing the domain organization and 44% amino acid identity. However, in contrast to protein S and the other vitamin K-dependent proteins, the expression of *Gas6* is low in liver, but high in lung, intestine, bone marrow and endothelial cells.

The vitamin K-dependent proteins share the Gla domain, containing several glutamic acids, which are γ-carboxylated in the endoplasmatic reticulum. The Gla domain is a common feature in several proteins involved in coagulation (Fig 1), and the Gla domain enables them to bind surfaces containing negatively charged phospholipids, on which many of the reactions of the coagulation cascade occur. In vivo, negatively charged phospholipids are present on the membranes of endothelial cells and activated platelets. The γ-carboxylation of the Gla domain is dependent on vitamin K, and in its absence, the Gla domains have impaired membrane binding. The anticoagulant drug
warfarin exerts its function by inhibiting the \(\gamma\)-carboxylation of several of the proteins of the coagulation cascade\(^8\).

**Figure 1**
The domain organization of Gas6, protein S, and other Gla-containing proteins.

The first translated amino acids of the Gas6 protein compose the signal peptide, which is cleaved off during secretion. The mature Gas6 protein consists of a N-terminal Gla domain, a loop region, four epidermal growth factor (EGF) domains and two laminin G (LG) domains.

The loop region of Gas6 is the region with lowest homology to protein S\(^2\). Thrombin cleaves protein S in the loop region, but no such cleavage has been reported for Gas6. EGF domains are found in over 600 proteins\(^9\), including several coagulation factors (Fig 1). Each EGF module has 6 cysteins with a characteristic binding pattern between Cysteins 1-3, 2-4 and 5-6\(^{10}\).
The LG domains constitute the C-terminal part of Gas6. LG domains are usually present in single modules or pairs, and are found in over 80 proteins. The two LG domains are together sometimes called the SHBG domain. It is called so due to the similarity with sex hormone binding globulin (SHBG), produced by the liver. SHBG binds hormones in circulation and prolongs their half-life.

An alternative transcript of Gas6 has been reported, with an insert of 129 basepairs between the last EGF domain and the SHBG domain. The expression of this splice variant, called Gas6sv can be seen in lung, brain, kidney and placenta where it makes up a small fraction of the total Gas6 expression. However, in the spleen, Gas6sv is the dominant form, but the role of this variant is not fully elucidated. The Gas6 promoter regions are defined, and an estrogen response element has been found upstream of the Gas6 gene.

**Protein S**

Gas6 is similar to the more widely known protein S which was discovered in 1977 when purifying coagulation factor IX and factor X from plasma. The purification method used included an absorption step using barium citrate, which precipitates proteins containing Gla domains. During the elution of factors IX and X, another protein peak was observed. The protein was purified and amino terminal sequencing revealed a new, Gla-containing protein, which was named protein S.

Protein S is mainly produced in the liver, but some expression can also be observed in endothelium, megakaryocytes, smooth muscle cells and osteoblasts.
The mature human protein S consists of 635 amino acids and is composed of a N-terminal Gla domain, a thrombin sensitive loop region, four EGF domains and two LG domains\textsuperscript{23}. The Gla domain anchors protein S to negatively charged phospholipids on which it can function as a cofactor to the activated protein C. The loop region is sensitive to thrombin and cleavage at Arg49 and Arg70 removes the cofactor activity to activated protein C\textsuperscript{5}. The LG domains in protein S bind with high affinity to the complement regulatory protein C4b binding protein (C4BP).

Protein S is reported to have anticoagulant effects on multiple steps in the coagulation cascade. The most studied effect is the function as a cofactor to activated protein C (APC). Thrombin activates protein C when bound to thrombomodulin, and APC inactivates factor Va and factor VIIIa, limiting further formation of thrombin. With protein S present, the affinity between APC and the membrane is increased tenfold, leading to more efficient inactivation\textsuperscript{24}. Protein S is also reported to have direct anticoagulant function on factor X\textsuperscript{25}, and an anticoagulant function through TFPI\textsuperscript{6}.

60-70 % of protein S in circulation is normally bound to C4BP\textsuperscript{26}. The C4BP-protein S complex has an octopus-like appearance with eight chains linked together by disulfide bonds in the central region\textsuperscript{27}. C4BP consists of seven $\alpha$-chains with complement regulatory activity, and of one $\beta$-chain that binds the SHBG domain of protein S\textsuperscript{28}. The affinity between the $\beta$-chain and protein S is around 0.1 nM\textsuperscript{29}. Thus, all $\beta$-chains in circulation are bound to protein S. C4BP inhibits complement by acting as a cofactor for factor I in degrading C4b and
C3b, and protein S-C4BP inhibits phagocytosis of apoptotic cells, as opposed to free protein S.

**Receptor tyrosine kinases**

RTKs comprise a large group of transmembrane proteins with the ability to transfer signals from the outside of the cell to the inside. When a ligand binds a receptor tyrosine kinase, two receptor chains are brought in close contact and will become phosphorylated on specific residues of the RTK. The phosphorylated domain will allow adaptor proteins to bind, which in turn will transfer the signal further into the cell. In the human genome, 58 RTKs have been found, grouped into twenty families due to homology.

**Figure 2**

Seven families of receptor tyrosine kinases.
The TAM family of receptor tyrosine kinases

The TAM family consist of three proteins: Tyro3, Axl and Mer. As the proteins have been of interest for many groups, working simultaneously and with different species, a plethora of names are in use. Tyro3 is called Sky, Rse, Brt, Tif, Dtk and Etk-2, Axl is also known as Ufo, Ark and Tyro7 and Mer is referred to as Eyk, Nyk or Tyro12. The whole family of proteins is called the TAM family (Tyro3, Axl and Mer), the Tyro3 family, or the Axl family. In this thesis, I will use the TAM family and Tyro3, Axl and Mer nomenclature.

The Tyro- names were given after an experiment using primers to conserved parts of RTKs. The primers were used to investigate the nervous system for presence of RTKs, and found several known RTKs and also 13 mRNAs of RTKs not yet described\(^36\). Three of the new mRNAs, Tyro3, Tyro7 and Tyro12 could not be assigned to any known family of receptors. However, the signalling domains of these three receptors all contained a common recognition motif and were denoted the Tyro3 subfamily.

The Axl gene was found as a gene able to induce chronic myeloproliferative leukemia\(^37\), and was later revealed to code for a RTK\(^38\). The gene was named Axl after the Greek anexelekto, meaning the uncontrolled. The same gene was also found by another group as a gene causing chronic myeloproliferative disorder, calling it Ufo, referring to its unknown function\(^39\), and the murine gene was given the name Ark\(^40\). The Axl gene is expressed in brain\(^36,41\), endothelial cells, heart, skeletal muscle, liver, kidney, testis and hematopoietic tissues\(^42\).
and cell lines from epithelial, mesenchymal and hematopoietic origin. Jia et al. identified the gene behind the oncogenic properties of the avian virus RPL30, and sequence analysis showed a high homology to Axl. After screening a human λgt11 library in E. Coli with an antisera against phosphotyrosine a human homologue to the RPL30 gene was identified. High expression was observed in monocytes, epithelium and reproductive tissue, and thus the protein was named Mer.

During March and April 1994, four groups independently published findings of a new RTK. They named the receptor tif, Sky, brt and rse, all describing the same protein. Expression is high in the nervous system, but can also be observed in ovaries and testis, endothelial cells and osteoclasts.

Tyro3, Axl and Mer share the same domain organization with two N-terminal immunoglobulin-like domains, two fibronectin type III domains, a transmembrane domain and an intracellular signalling domain. The latter contains a KW(I/L)A(I/L)ES motif which is specific for the TAM family. Both Ig and FNIII domains are common in RTKs and are also present in neural cell adhesion molecules.
The Tyro3, Axl and Mer proteins contain 890, 894 and 999 amino acids, respectively, which theoretically should encode proteins with a size of 100-110 kDa. Due to extensive glycosylation, the full-length Axl and Tyro3 proteins migrate as 140 kDa \(^{57,58}\), and Mer as 205 kDa \(^{59}\).

**Gas6 and protein S as ligands of the TAM family**

Gas6 was found to function as a ligand to the Axl receptor in 1995. Axl-bearing cells were exposed to media from 70 different cell lines in search for a factor that could activate the receptor, and media from two cell lines were able to stimulate Axl. The cell media was purified on the basis of the Axl stimulatory activity, and after several purification steps, a single protein band was sent to mass spectrometry, which identified the Gas6 protein \(^{60}\). Further studies showed that Gas6 bound and activated the Tyro3 \(^{61,62}\), and Mer receptors \(^{63}\).
The binding of protein S to the TAM receptor family has been debated. Protein S was identified as a ligand to the TAM family of receptors, but as the study used human protein S to stimulate murine Tyro3, the relevance of this finding has been questioned. However, Protein S has been reported to activate TAM receptors in several animal models and an oxidized, oligomeric form of protein S has been shown to activate Mer and induce phagocytosis, suggesting that oligomerization is crucial for signalling.

The domains of Gas6 able to stimulate the TAM receptors have been defined using deletion constructs of Gas6. The C-terminal portion is enough to stimulate the TAM receptors, and Gas6sv can also stimulate receptors. Even so, Gas6 expressed in the presence of warfarin, lacking gamma carboxylated glutamic acids is unable to activate the receptors on cells to give cellular effects. The affinity of the human Gas6-TAM receptor interaction has been estimated by several groups. Nagata et al. estimated the Gas6-Axl affinity to 1 nM and the Gas6-Tyro3 affinity to 10.8 nM. Chen et al. determined the affinity for Gas6 to 1.6 nM for Axl, 3.6 for Tyro3 and 9.7 for Mer. Fisher et al. report 0.053, 0.031 and 0.304 nM for the three receptors respectively. Wimmel reported 0.178 nM for Gas6 and Axl, and we have estimated the Gas6-Axl affinity to 0.4 nM (Paper I).
Table 1
Reported strength of the Gas6 interaction with the TAM receptors.

<table>
<thead>
<tr>
<th>Equilibrium constant of Gas6 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axl</td>
</tr>
<tr>
<td>1.0</td>
</tr>
<tr>
<td>1.6</td>
</tr>
<tr>
<td>0.053</td>
</tr>
</tbody>
</table>

A number of crystals revealing the three-dimensional structure of Gas6 and its receptors have been published. The first published crystal demonstrated the structure of the LG domains of Gas6. The fold was similar to previously described LG-containing proteins and indicated which amino acids that could influence binding to receptors, and when Leu620 was mutated to an alanine, the affinity towards Axl decreased tenfold\(^81\).

 Alone, the Ig domains of Tyro3 can bind Gas6, and a crystal of the Tyro3 Ig domains has also been presented\(^82\). A complex crystal containing the LG domains of Gas6 and the Ig domains of Axl has been presented. In this crystal, two pairs of Ig and LG domains form a 2:2 complex, with one major binding site between Ig1 and LG1, and a minor between Ig2 and LG1\(^83\).

### Soluble TAM receptors

Several receptors exist in soluble forms, consisting of the extracellular regions of the receptor. The soluble receptors can remove the ligand from cell bound receptors and thus inhibit signalling\(^84,85\), and several experiments have utilized a extracellular, soluble form of Axl (sAxl) or a dimeric Axl (Axl-Fc) as specific inhibitors for Gas6.
signalling. Soluble receptors can be produced by alternative splicing or by proteolysis of the full-length receptor. The Axl receptor is cleaved just outside the membrane, and shedding of soluble Axl can be induced by treatment with phorbol esters. Several mouse cells and organs release sAxl constitutively. Decreased shedding of sAxl could be observed during treatment of the broad metalloproteinase inhibitor GM6001, the more specific inhibitor GW280264X (targeting TACE and ADAM10) and also siRNA against ADAM10. The cleavage site of Axl was localized with use of deletion mutants, lacking parts of the extracellular domain close to the membrane. In mouse serum, Gas6 could be co-immunoprecipitated with anti-Axl antibodies, which indicated that the proteins circulate in complex. Human dendritic cells shed sAxl upon inflammatory stimuli. sAxl is shedded from human cell lines, and is present in human plasma where it binds Gas6 (see Paper I). Soluble Mer (sMer) is reported to be present in mouse and human serum. Similar to sAxl, the shedding of sMer could be increased with phorbol esters and LPS. The shedding was inhibited by TAPI, an inhibitor of the TACE metalloproteinases. The Merk gene, (encoding the Mer protein) contains a additional polyadenylation site after the extracellular domain, indicating that sMer could be translated without the C-terminal parts of the protein. Expression of this extracellular domain alone has been reported as unpublished observations.

**Cellular effects of Gas6 signalling**

Gas6 binding to the TAM family induces receptor dimerization. The intracellular signalling domains are brought into close proximity and become phosphorylated on specific tyrosine residues. Stimulation of
Tyro3 can stimulate the Src family\textsuperscript{92} as well as Erk\textsuperscript{93}, and has in yeast 2-hybrid systems been shown to interact with PI3K\textsuperscript{94} and RanBPM\textsuperscript{95}. In Axl, the tyrosine residues in positions 779, 821, and 866 are known to be phosphorylated, which leads to signalling through the Grb2 and PI3K pathways\textsuperscript{96,97}. Activation of Mer leads to phosphorylation of the tyrosine residues at 749, 753 and 754\textsuperscript{98}, and to interaction of PLC, PI3K, Shc, Grb2\textsuperscript{99} and Vav\textsuperscript{100}.

The cellular effects initiated by Gas6 signalling are different in different cell types and can work synergistic with other signals. Gas6 signalling is of importance in many physiological and pathological situations, and below is a brief description of some of the more studied areas.

**Antiapoptosis and mitogenesis**

Several studies have been presented on the antiapoptotic and mitogenic effects of Gas6 signalling. These effects have been documented in fibroblasts\textsuperscript{77,101-103}, different endothelial cells\textsuperscript{74,76,104-106}, vascular smooth muscle cells\textsuperscript{75,107,108}, oligodendrocytes\textsuperscript{109,110}, Schwann cells\textsuperscript{111}, lens epithelial cells\textsuperscript{112}, neurons\textsuperscript{113,114} and liver cells\textsuperscript{115-117}. Gas6 decrease apoptosis after serum starvation\textsuperscript{74,77,101,104,107,113,115} and TNFα-treatment\textsuperscript{106,110,112} in several cell types. Gas6 has a mitogenic effect\textsuperscript{75,77,101,111} but the Gas6 effect is lower compared to PDGF and FGF4\textsuperscript{101}.

The TAM receptors were found as transforming genes, and the role of TAM receptors and Gas6 in cancer has been studied by several
groups. Presence of Gas6 and the TAM receptors have been observed in many malignancies, including leukemia\textsuperscript{118}, cancer of the thyroid\textsuperscript{119,120}, lung\textsuperscript{80}, uterus\textsuperscript{121}, endometrium\textsuperscript{122}, ovary\textsuperscript{123}, prostate\textsuperscript{124-127}, gastric cancer\textsuperscript{87}, breast cancer\textsuperscript{128}, Kaposi’s sarcoma\textsuperscript{129}, malignant gliomas\textsuperscript{130,131} and renal cell carcinoma\textsuperscript{132}.

Gas6 induces proliferation and survival in breast\textsuperscript{133} and prostate cancer cells\textsuperscript{124,126}. Several animal models have also indicated the role of TAM receptors. In mouse models of glioma\textsuperscript{131}, breast cancer\textsuperscript{134}, hepatocellular carcinoma\textsuperscript{135} and metastatic ovarian cancer\textsuperscript{136}, high expression of Axl is detrimental, and blocking Axl expression on transcriptional or protein level increase survival. Gas6 is mitogenic for tumors, and implanted tumors grow faster in wildtype than Gas6\textsuperscript{-/-} mice\textsuperscript{137}, as infiltrating macrophages released Gas6 to the tumor.

Presence of Gas6 and the TAM receptors have clinical implications for cancer patients. Low expression of Axl mRNA indicate a good prognosis in patients with renal cell carcinoma\textsuperscript{132}. High Axl expression in breast cancer\textsuperscript{134}, pancreatic adenocarcinoma\textsuperscript{138}, malignant glioma\textsuperscript{130} and esophageal adenocarcinoma\textsuperscript{139} is a negative prognostic factor. However, in breast cancer, high Gas6 expression is associated with smaller tumor size and decreased metastases\textsuperscript{140}.

Inhibition of RTKs has been shown to be a viable way of treating several cancers\textsuperscript{141-143}. Inhibiting Axl with antibodies and shRNA leads to decreased proliferation and invasiveness in animal models\textsuperscript{129,144-146}. Axl-inhibitory small molecules are under development, and have been shown to inhibit breast cancer metastasis in mice\textsuperscript{147}.
**Phagocytosis & Migration**

Gas6 can act as a bridging molecule with the Gla domain binding negatively charged phospholipids, coincident with LG domains binding a TAM-bearing phagocytic cell. Phosphatidylserine (PS) normally resides in the inner leaflet of the cell membrane, but as cells become apoptotic, PS accumulates in the outer leaflet. Without proper removal of apoptotic cells, secondary necrosis ensues and leads to inflammation. Gas6 binds PS in microtiter plates, and monocytes bind PS-coated microtiter plates when Gas6 is present, but not in its absence. Liposomes and apoptotic cells, both containing PS are taken up more efficiently by mouse macrophages when Gas6 is present.

Macrophages with a cytoplasmatic truncation of Mer are deficient in phagocytosis of apoptotic thymocytes. Macrophages mainly use the Mer receptor for phagocytosis, whereas dendritic cells use Tyro3 and Axl, Glial cells use Axl and Mer, and the Sertoli cells in the testis use all three receptors.

The TAM receptors are involved in the phagocytosis of the outer segments of photoreceptors by the retinal pigmental epithelium (RPE) cells. Without trimming of the photoreceptors, they overgrow and eyesight is impaired. The Royal College of Surgeons rat strain has a hereditary retinal degradation, which is caused by a mutation in the *Mertk* gene. The mutation inserts a premature stop codon, truncating the Mer protein, thus hindering effective phagocytosis. The phagocytosis of the outer segments in cell cultures can be inhibited by targeting Gas6 or Mer. The Gla domain of Gas6 bind to the outer
segments, and stimulates phagocytosis through Mer, present on the RPE cells. However, Gas6 mice do not become blind, but mice lacking Mertk do, indicating that protein S might play a role. Also in human RPE cells, phagocytosis can be decreased by using anti-Gas6 or anti-Mer antibodies. The genome of several families with hereditary retinal dystrophies have been investigated and revealed several mutations in the Mertk gene.

Gas6 can induce migration in Axl expressing cells, including VSMC, neurons, and dendritic cells, but is reported to inhibit migration in mouse fibrosarcoma cells, renal carcinoma cells, and to inhibit chemotaxis of endothelial cells, showing that the migration is highly dependent on cell type.

**Gas6 and mesangial cell proliferation**

Hyperproliferation of mesangial cells in the kidney is a hallmark of glomerular disease. Several studies indicate that mice show lesser symptoms of kidney disease when given warfarin, Axl-Fc, or are deficient in Gas6. In the first published study, mesangial cells were treated with medium from Gas6-producing cells and started to proliferate. However, this proliferation could be inhibited by treating the Gas6-producing cells with warfarin. Gas6 and Axl was later found to be upregulated in the mesangial cells in a mouse model of experimental glomerulonephritis. The STAT3 dependent hyperproliferation of mesangial cells could be inhibited in vivo with Axl-Fc or warfarin. In a related model of nephrotoxic nephritis, Gas6 mice survived to a higher degree and showed less albuminuria,
but infusion of Gas6 brought back the symptoms to the level of wildtype animals\textsuperscript{174}.

Experimentally induced diabetes nephropathy can also be improved with warfarin. Warfarin decreases mesangial cell area and lowers urinary albumin excretion and Gas6\textsuperscript{-/-} mice were also protected\textsuperscript{175}.

Also in aldosterone induced hypertension, Gas6\textsuperscript{-/-} mice fare better and show less albuminuria and kidney inflammation\textsuperscript{176}. Kidney expression of Gas6 is increased during chronic rejection of transplanted kidneys\textsuperscript{177}, lupus nephritis, glomerulonephritis and IgA nephropathy\textsuperscript{178}. These findings indicate that Gas6 signalling can be detrimental in several renal diseases, and the researchers suggest that low dose warfarin could be beneficial for these patients\textsuperscript{179}.

**Gas6 and TAM in the vasculature**

Axl and Gas6 are expressed by numerous cell types in the vascular wall, including endothelial cells, smooth muscle cells and fibroblasts\textsuperscript{52,102,106,107,180}. Gas6 and Axl are important for vessel integrity and injury response in the vessel wall, and Axl is upregulated after balloon injury\textsuperscript{181,182}. Animals deficient in Axl or Gas6 display impaired vessel integrity and have increased vessel leakage compared to their wildtype littermates\textsuperscript{18}. Mice deficient in Axl also show decreased intimal proliferation after carotid ligation\textsuperscript{183,184} and attenuated intimal growth during hypertension\textsuperscript{185}.

The role of Gas6 in atherosclerosis has been investigated by comparing mice deficient in ApoE with mice deficient in ApoE and Gas6. The plaques in Gas6 deficient mice had more collagen and smooth muscle cells and less macrophages, indicating higher stability of the plaque in the absence of Gas6\textsuperscript{186}. Interestingly, polymorphisms
in the human *Gas6* gene are protective to stroke in two studies, and polymorphisms in the Mertk and Tyro3 genes are protective against carotid atherosclerosis. In an animal model of blood brain barrier stability, protein S induced phosphorylation of Tyro3 is reported to be protective.

**Regulation of inflammation**

Cell experiments show that Axl stimulation by Gas6 can inhibit release of proinflammatory cytokines from human macrophages, dendritic cells, sertoli cells, and glial cells, thus limiting the immune response. In bone marrow derived dendritic cells Gas6 induces upregulation of SOCS proteins, known for their suppression of cytokine signalling. Interestingly, interferon signalling upregulates Axl mRNA transcription in dendritic cells, enabling a negative feedback loop.

The role of Gas6 for endothelial activation is complex. Endothelial cells activated by TNFα or phorbol esters showed less granulocyte binding after treatment with high doses of Gas6, but animals deficient in Gas6 do not upregulate ICAM-1 and VCAM-1 after TNFα stimulation and exhibit less transmigration of leucocytes.

**Gas6/protein S/TAM-deficient animals**

To be able to study the complex role of the Gas6/protein S – TAM system, genetically altered mice lacking one or several of these proteins have been developed. The animals are useful since they can reveal new and unexpected physiological roles of the proteins studied. Mice lacking either Tyro3 or Axl display milder immunological aberrations, and animals lacking Mer exhibit a hyperactive response.
to LPS and have higher cytokine secretion compared to wildtype littermates\textsuperscript{197}. The single knockouts were still fertile, and breeding was directed towards double and triple knockout mice. The double knockouts show increased autoimmune manifestations, and the immune system of the triple knockout is severely deranged\textsuperscript{198}. Multiple organ defects were observed, including blindness and infertility\textsuperscript{57}. In one-year old mice, the spleen of a triple knockout was ten times the size of the wildtype animal. This growth was due to proliferation of B and T cells, which filled the normal immunological compartments, but also established ectopic colonies in all organs investigated\textsuperscript{198}. The animals developed autoimmune disorders with antibody deposition in the glomeruli, and presence of antibodies against DNA, collagen, cardiolipin and $\alpha$-phosphatidylinositol.

When a mouse deficient in Gas6 was reported, no obvious phenotype could be observed. However, in thrombosis models, the Gas6\textsuperscript{-/-} mice had smaller thrombi and lower mortality\textsuperscript{199}. The platelets were found to be less responsive to agonists and platelet aggregates from Gas6\textsuperscript{-/-} mice were less densely packed. Interestingly, addition of anti-Gas6 antibodies could protect mice equally well as total deficiency of Gas6. This study was followed up by a study evaluating hemostasis in animals deficient in all three TAM receptors. These animals were also protected in thrombosis models and had less responsive platelets\textsuperscript{200}. Studies on human platelets have also indicated a role for Gas6 during platelet activation\textsuperscript{201}, but the role is debated\textsuperscript{202,203}. Further studies showed that TAM\textsuperscript{-/-} mice have half the number of thrombocytes compared to wildtype littermates. Megakaryocytes were found to
express all TAM receptors and megakaryocytes lacking all the receptors produced less proplatelets. Mice deficient in Gas6 were also found to have lower levels of erythroid cells, and the hematocrit recovered slower from induced anemia. When inducing acute hemolysis with phenylhydrazine, also Axl and Mer knockouts are slower to regain normal hematocrit. Animals deficient in Gas6 show altered endothelial response to inflammatory stimuli. Gas6−/− endothelium activated with TNFα had less upregulation of p-selectin, VCAM-1 and ICAM-1 than wildtype endothelium and adhesion by platelets and leukocytes is decreased. The Gas6−/− animals showed less inflammation following LPS injection and slower rejection of non-matched transplanted hearts. Graft versus host disease is slower in Gas6−/− animals compared to wildtype, presumably due to the slower extravasation of leucocytes, decreasing the rate of organ damage. Gas6 deficient mice also have a higher baseline of many inflammatory cytokines.

Mice deficient in protein S do not survive embryogenesis due to severe hemorrhages. Heterozygous PROS1+/− mice however, survive but have decreased levels of protein S in plasma and are more susceptible to induced thrombosis. The vasculature in the PROS1−/− embryos is disorganized and less smooth muscle actin can be found around the vessels at embryonic day 13.5. Furthermore, PROS1+/− mice had defective vasculature, observed by dye leakage from the vessels. This leakage was also found in endothelial PROS1−/− knockouts and Gas6−/− and Axl−/− mice, indicating a role for these proteins for vascular integrity.
**Studies of plasma concentrations of Gas6**

As Gas6 was indicated to be important for platelet function, early studies focused on investigating human platelets, which do not contain large amounts of Gas6\(^{201,202}\). However, plasma was found to contain 18 ng/ml of Gas6, and patients treated with warfarin had decreased Gas6 levels in plasma\(^{202}\). Another ELISA was published, which estimated the plasma concentration of Gas6 to 50-63 ng/ml\(^{208}\). This ELISA was later used for relating the Gas6 concentration with different coagulation parameters, but found no statistically significant correlation in the investigated patients\(^{203}\). However, patients with aspirin pseudoresistance were overrepresented in patients with high Gas6\(^{209}\), and Gas6 was influenced by oral contraceptives\(^{208}\). Plasma from patients with acute coronary syndromes were also investigated, but were not different from a control population\(^{210}\).

Patients with severe sepsis were evaluated by two groups, and both found increased Gas6 in patients with sepsis, correlating with degree of organ dysfunction, but the concentrations of Gas6 reported were 50 ng/ml\(^{211}\) and 100 pg/ml\(^{212}\). These studies were followed up by a Japanese group, measuring Gas6 in patients with acute pancreatitis, another condition characterized by inflammation and organ dysfunction. These patients had triple Gas6 concentration compared to a control group\(^{213}\).

A Gas6 ELISA made of commercially available reagents was presented\(^{214}\), and was used to investigate cerebrospinal fluid from patients with neurological diseases, revealing that patients with chronic inflammatory demyelinating polyneuropathy have increased Gas6\(^{215}\). The same group investigated patients with acute dyspnea with
the Gas6 ELISA to elucidate if Gas6 could be used for diagnosis, and high Gas6 was observed in patients with heart failure and systemic infections.\textsuperscript{216} Patients with acute coronary syndrome were investigated by a Chinese group, finding that patients with stable or unstable angina, and also patients with acute myocardial infarction had decreased plasma Gas6 to a control group.\textsuperscript{217} Patients with impaired glucose tolerance and type 2 diabetes have also been found to have decreased Gas6.\textsuperscript{218} We have recently shown that patients with renal cell carcinoma with higher Gas6 and sAxl have poorer survival compared to patients with low Gas6 and sAxl.\textsuperscript{132} A recent study evaluating patients with Systemic Lupus Erythematosus (SLE) indicate that the Gas6 concentrations are similar to controls, but patients with high disease activity have increased Gas6.\textsuperscript{219}
The present investigation

Overview

The overall aim of my project was to gain structural and functional insight in the TAM family of receptors. Several studies from the lab have been focused on understanding the structural properties of proteins, many times using site directed mutagenesis.

In 2005, when I started in the lab, methods were set up for expressing both protein S and Gas6, and there was a wide collection of antibodies for these proteins, but there were no methods to express the TAM receptors. One could have gone for commercial reagents, but as many experiments demand large quantities of protein, we decided it would make sense to produce the reagents ourselves. Purified TAM receptors could be used for binding studies, signalling experiments and immunizing animals to obtain antibodies. The antibodies could be used for detection of protein, from western blotting, to immunohistochemistry and ELISAs.

The work started with making plasmids with the genes coding for sAxl, sTyro3 and sMer, and transfecting cell lines with these plasmids. sAxl and sTyro3 showed good expression and purification began. Despite several attempts to express sMer, we could not get sufficient expression, and the sMer project was put on hold. Meanwhile, sAxl and sTyro3 were expressed in large scale, purified to single band on silver stained SDS-PAGE, and used for immunization of rabbits. With the anti-Axl antibodies, we soon found out that several cell lines express sAxl, and that sAxl is present in human
circulation, and the work leading to paper I started. With functional ELISAs for Gas6 and sAx1, it was easy to investigate patient materials, and as we got interesting results, we followed that path, leading to papers II-V. The antibodies against Ax1 have also been useful for immunohistochemistry in several projects.
Paper I – Gas6 in complex with soluble Axl

Background
My work in the lab began with expression of the extracellular domains of the Axl protein. A vector with full-length cDNA for Axl was used as template, which was amplified with specific primers to add restriction sites and a thrombin sensitive His$_6$-tag. The pcr product was ligated and inserted in a pcDNA3.1 vector, which was transfected into HEK293 cells. sAxl Expression was confirmed by using a commercial affinity purified anti-Axl antibody, and the colony expressing highest amounts of sAxl was chosen for large scale expression.

The first purification step was precipitation with saturated ammonium sulphate. The pellet was resuspended and dialyzed in a low salt buffer to allow for anion exchange chromatography. The fractions containing sAxl from the anion exchange were pooled and applied to a nickel affinity column. After elution, the sAxl-containing fractions from this column was concentrated and further purified using gel filtration. The resulting protein could be seen as a single band on a silver stained gel. After removal of the His$_6$-tag, the purified sAxl protein was used to immunize two rabbits to obtain antibodies against Axl. After several immunizations, the two antisera (041 and 042) contained high titers of anti-Axl antibodies and the antibodies were collected on Protein A and Protein G columns. The antibodies bound sAxl in Western blotting and in microtiter plates with good specificity and low background.

Parts of each antisera were biotinylated to allow visualization with streptavidin-coupled horseradish peroxidase. Different concentrations were tested to identify the optimal concentrations of antibodies for an Axl ELISA. The recombinant purified sAxl was quantified using total
amino acid analysis after acidic hydrolysis, and a serial dilution of the sAxl was used as standard in the ELISA.

Results and Discussion
Human serum and plasma was investigated with the Axl ELISA. A positive signal could be detected in all the samples tested, corresponding to a concentration around 0.6 nM. To evaluate that the ELISA was measuring the correct protein, recombinant sAxl was added to serum samples, and the signal increased accordingly. To determine the specificity of the ELISA, samples were immunoprecipitated with a commercially available anti-Axl antibody, which effectively removed the sAxl signal in these samples. To further show specificity of the antibodies, the 042 and 041 antibodies were coupled to NHS-activated columns. Large amounts of plasma were added to the 042 column, followed by extensive washing and elution. The eluate was added to the 041 column which was washed and eluted similarly. The collected sample was evaluated by SDS-PAGE stained with colloidal coomassie. A 65 kDa band was excised and sent to mass spectrometry, which could confirm the identity of the band as Axl. Four peptides, all from the extracellular domain could be identified. Immunoprecipitation of human serum with the antibodies revealed a 65 kDa band, and several cell lines also seemed to express sAxl, although the glycosylation pattern differed slightly.

Due to the high affinity between Axl and Gas6, we used gel filtration to determine if Gas6 and sAxl are complexed in human circulation. The elution patterns of recombinant Gas6 and serum Gas6 was compared, and recombinant Gas6 eluted later than serum Gas6,
indicating that serum Gas6 was a part of a larger complex. The recombinant sAxl eluted as serum sAxl, except a small part of the serum sAxl that eluted in the Gas6 fractions. Antibodies to Gas6 displaced sAxl to the void volume, and antibodies to Axl displaced Gas6, indicating that Gas6 and sAxl were in complex. In an ELISA, with catching anti-Axl antibodies, and detecting anti-Gas6 antibodies, a signal was detected in the Gas6 peak of serum and plasma.

Immunoprecipitation of serum was performed to precipitate the complex. After immunoprecipitation with an anti-Gas6 and an anti-Axl antibody, similar amounts of Gas6 could be immunoblotted, indicating that practically all Gas6 is in complex with Axl. Immunoblotting with anti-Axl antibodies revealed that much more sAxl is precipitated with anti-Axl compared to anti-Gas6 antibodies, indicating excess of sAxl in human serum. When testing serum samples with the complex ELISA, an increased signal could be seen after adding Gas6 to the serum, but not after adding sAxl, indicating that Gas6 is the limiting factor for complex formation.

To further show presence of the complexes, native gels were used to investigate the migration of Gas6 alone and together with sAxl and Axl-Fc. Gas6 travelled shorter distances when the sAxl and Axl-Fc were present, indicating that a larger complex was formed.

To rule out that sTyro3 or sMer took a part in complex formation, gel filtration of serum was performed with and without anti-Gas6 antibodies. No change in the elution of sTyro3 or sMer could be observed, indicating that sAxl is the main binder of Gas6 in human serum.

These findings indicate that the Gas6 present in human serum is bound to sAxl and suggests that serum Gas6 is incapable of
stimulating cell-bound receptors. The signalling of Gas6 ought be local to its nature, as Gas6 leaked to the circulation would be bound by the excess sAxl. Earlier research in mice models have indicated that Gas6 is an important mediator for platelet activation, and that soluble TAM receptors or antibodies against Gas6 could be useful against thrombosis. This study indicates that Gas6 in circulation isn’t available for binding in humans. Further studies on TAM receptor content of human platelets or Gas6 release by endothelium could be very useful to better understand platelet activation, as some studies suggest that Gas6 has a role in human platelet activation\textsuperscript{201}. The developed ELISA to quantify sAxl in human sera is a useful tool to investigate the role of sAxl in a number of human conditions. As the lab have setup an ELISA for Gas6, we found it natural to investigate these two proteins in a number of patient materials.
Paper II - Gas6 and sAxl in patients with Abdominal Aorta Aneurysms

Background
Abdominal Aorta Aneurysm (AAA) is a disease characterized by weakening of the abdominal aorta, causing the vascular wall to bulge outwards, resulting in increased vessel diameter. Inflammation, mechanical stress and proteolytic degradation of the aortic wall are all proposed to be of importance for the development of AAAs, but the mechanisms are not fully elucidated. High age, smoking, heredity, coronary heart disease, high cholesterol and blood pressure are all risk factors for development of AAA. Increased diameter of the AAA increases the likelihood of rupture, causing massive bleeding, which often is lethal. AAAs are present in approximately 5% of elderly men and ruptured aorta is estimated to be responsible for 2% of all deaths in the Western world.

Surgery for all aneurysms larger than 5.5 cm is the recommended treatment for all patients suitable for operation. Due to the suggested role for Gas6 and Axl in the vasculature, we decided to evaluate the concentrations of these proteins in patients with large and small aortic aneurysms and compare them to a control population. The study included 123 patients with large AAAs, 122 with small AAAs, and 141 healthy controls.

Results and discussion
Compared to the control population, Gas6 was increased and sAxl decreased in patients with large aneurysms, with the small aneurysms having intermediate Gas6 and sAxl concentrations. The diameter of
the AAA correlated positively to Gas6 and negatively to sAxl concentration. Due to Gas6 being bound to sAxl, we calculated the Gas6/sAxl-ratio and this ratio correlated better than Gas6 or sAxl to the diameter of the AAAs. Thus, the Gas6/sAxl ratio was high in the patients with large AAAs, and 40% of the patients with large AAA had higher Gas6/sAxl-ratios compared to the highest ratio in the control group. The Gas6/sAxl-ratio is not specific enough to allow screening of AAAs, as 60% of all patients with large AAAs have Gas6/sAxl ratios in the normal range. The causes of this altered ratio remains to be elucidated, but increased Gas6 is observed during severe inflammatory conditions\textsuperscript{211-213}. Gas6 and Axl are important for vascular integrity\textsuperscript{18} and involved in vascular remodelling\textsuperscript{181,183}, likely to take place during the development of AAA. The patients with high Gas6/sAxl-ratio might constitute a subgroup with different AAA properties, with higher involvement of the Gas6/Axl-system.

The study demonstrated that Gas6 and sAxl were altered in the patient group and encouraged us to further study the role of Gas6 and sAxl in patient materials.
Paper III - Gas6 and sAxl in Critical Limb Ischemia

Background
Critical limb ischemia (CLI) is a disease caused by atherosclerosis. Atherosclerosis is characterized by fat accumulation under the intima of the larger vessels, causing inflammation\(^{225}\). Atherosclerosis causes several diseases, including coronary heart disease and cerebrovascular disease, and patients with critical limb ischemia have high comorbidities with these diseases\(^{226}\). CLI is characterized by low blood supply to the tissues, which leads to rest pain, ulcers or gangrene in the affected limbs\(^{227}\). The diagnosis of CLI is made after measuring blood pressure in ankles and toes or by transcutaneous measurements of the oxygen pressure\(^{228}\). CLI is present of 0.26% in the population between 40 and 69 years of age\(^{229}\), and patients have a high mortality, often due to cardiovascular disease and stroke\(^{230}\). The treatment of CLI includes revascularization when possible, as well as controlling atherosclerotic risk factors as smoking, hypertension, hyperlipidemia and diabetes mellitus. In our study, 189 patients with CLI and 204 controls were included.

Results and discussion
Patients with CLI have increased Gas6 and sAxl compared to healthy controls, and both Gas6 and sAxl correlated with inflammatory markers as C-reactive protein, interleukin-6, TNF\(\alpha\) and neopterin. Gas6 and sAxl were increased in patients who have had ulcers, were amputated, had gangrene or angina. A small number of patients were investigated with echocardiography and in these patients, Gas6 correlated strongly to left heart strain. Patients who died within three
years of sampling had increased Gas6 and sAxl compared to the survivors. Gas6 and sAxl predicted mortality independent of age and gender, and Gas6 was also independent to many known risk factors of CLI, indicating a role in the disease. This study shows that Gas6 and sAxl correlate to several inflammatory markers and many aspects of CLI.

Gas6 has earlier been shown to be important for cortisone induced heart hypertrophy\textsuperscript{17c}, and the strong correlation to left heart strain indicates that Gas6 might be of importance for human heart remodelling. Only 35 patients were investigated with echocardiography, so a larger study on patients with heart insufficiency would be enlightening for the role of Gas6 in heart remodelling. sAxl correlated strongly with neopterin, which indicates that sAxl and neopterin release are connected in CLI, which can be a useful starting point when elucidating the mechanisms of sAxl shedding.
Paper IV - Gas6 and sAxl in Sepsis and SIRS

Background
Sepsis is a complex disease, defined as presence of infection and systemic inflammatory response syndrome (SIRS). A patient has SIRS when two or more of the following criteria are fulfilled: (1) Temperature above 38 °C or under 36 °C; (2) Heart rate above 90 beats per minute; (3) Breathing frequency above 20 breaths per minute, or PaO$_2$ less than 32 mm Hg or (4) White blood cell count above $12^{10}$ or below $4^{10}$ per liter, or the presence of more than 10% of immature neutrophils. The patients are treated with antibiotics to eradicate the infection, and fluid replacement to avoid shock, and otherwise given supportive treatment in case of organ failure. Controlling glucose and countering anemia does also increase survival. Increased plasma concentrations of Gas6 have earlier been reported in two studies of sepsis, but sAxl has never been measured. Due to the complex between these two molecules, we decided to evaluate the concentrations of both molecules in patients with sepsis and related conditions. The Division of Infection Medicine at Lund University has a well-characterized sepsis material consisting of blood samples from 232 patients with severe sepsis, sepsis, infections and SIRS and 100 blood donors as controls.

Results and discussion
All patient groups showed approximately doubled Gas6 concentrations compared to healthy controls, whereas sAxl is increased by around 20%. Our results confirm that Gas6 is increased in patients with sepsis, but also show that patients with milder
infections have Gas6 levels similar to the sepsis patients. Gas6 is increased in patients developing organ failure and patients in need of intensive care, indicating that increased Gas6 correlates with severe disease. Plasma sAxl is altered in the patients, but the increase is lower compared to Gas6, indicating that Gas6 can travel longer before complexed to sAxl, inducing more signalling during sepsis. Again, Gas6 and sAxl correlate to markers of inflammation, and especially Gas6 seems to behave as an acute phase protein.
Paper V - Gas6 and sAxl in systemic lupus erythematosus

Background
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with symptoms including rash, arthritis, anemia, nephritis and serositis\(^2\). The disease is associated with impaired clearance of apoptotic cells\(^{235,236}\) and antibodies directed to nuclear antigens\(^{237}\), but the etiology of the disease is not fully elucidated. SLE patients are predominantly female and African or Asian descent is overrepresented amongst the patients\(^{238}\). SLE is usually treated by immunosuppression with corticosteroids, cyclosporine or antimalarials, but a new generation of drugs as TNF\(\alpha\) blockers and other specific therapies based on monoclonal antibodies are coming into the clinic\(^{239}\).

Mice deficient in the TAM receptors develop several symptoms reminiscent of SLE, including deficient uptake of apoptotic cells\(^{151}\), glomerulonephritis and antibodies to DNA and phospholipids\(^{198}\). As Gas6 and the TAM receptors are of importance for immune regulation, we measured Gas6 and sAxl in a 96 SLE patients with a wide range of symptoms to evaluate the role for Gas6 and sAxl in the disease.

Results and discussion
In the 96 patients, the plasma concentrations of Gas6 and sAxl correlated with the disease intensity estimated by the SLEDAI-2K index. For 45 of the patients, two samples were available, one with high and one with low SLEDAI. Gas6 and sAxl were significantly increased in the high SLEDAI sample. Gas6 and sAxl correlated to
sedimentation rate, C-reactive protein and negatively to hemoglobin. Especially patients with glomerulonephritis or anti-DNA antibodies had increased levels of Gas6 and sAxl. The study shows that Gas6 and sAxl correlate with disease intensity in SLE, indicating a role in the disease, probably linked to inflammation.
Future perspectives

Gas6 and the TAM receptors are important for many physiological and pathological processes. The main findings of my PhD project are that Gas6 is bound to sAxl in human circulation, that Gas6 and sAxl levels are increased during various inflammatory conditions. Released Gas6 can influence the adjacent cells, before sAxl can inactivate it, but the site of Gas6 release is still poorly defined. We have preliminary data indicating that TNFα-activated endothelial cells don’t upregulate their Gas6 expression on the mRNA level, arguing for that the main Gas6 expression in inflammation come from other cell types. Systematic studies of cells being exposed to proinflammatory stimuli could reveal cell types involved in the Gas6 production.

The release of sAxl also remains poorly defined. In the CLI material, neopterin correlated strongly to sAxl, which indicates that the release of sAxl could be linked to activated macrophages. Dendritic cells have been reported to shed sAxl upon inflammatory stimulation, but macrophages might induce considerable sAxl shedding, and should be further investigated to reveal if this is a direct or an indirect effect. Warfarin seems to inhibit Gas6 function in some animal models, and further characterization of mouse and human Gas6 produced during treatment with low dose warfarin would be interesting. As low dose warfarin interferes with formation of functional Gas6, it might be an interesting experimental drug in animal models, as shown before with several kidney manifestations. As animal models for AAA, CLI, Sepsis and SLE exist, it is tempting to evaluate warfarin treated...
animals to determine if lack of functional Gas6 is making a difference in those animal models.

Due to the findings in the patient materials, we believe that further studies of Gas6 and sAxl in other diseases are motivated. Vasculitis, multiple sclerosis and gout would be interesting to study to widen our knowledge of Gas6 and sAxl in inflammatory conditions. Soluble Mer and Tyro3 seems to be present in circulation, and systematic studies of these proteins might also give us additional clues of the role of the TAM system in human physiology.
Populärvetenskaplig sammanfattning

Cellerna i vår kropp kommunicerar med varandra genom att skicka ut substanser, som binder till receptorer på andra celler. Min forskning har handlat om en sådan substans som heter Gas6, och dess receptorer Tyro3, Axl och Mer, som gemensamt kallas TAM-receptorerna. Receptorerna sitter genom cellens vägg och när Gas6 binder en av sina receptorer, så förändras de inre delarna av receptorn, vilket drar igång processer inne i cellen. Gas6 och TAM-receptorerna är viktiga för cellöverlevnad, reglering av immunförsvaret och för blodkärlens väggar.


Eftersom vi vet ganska lite om Gas6 och sAxl i olika sjukdomar, beslöt vi oss för att mäta sAxl och Gas6 i patientmaterial för att se om
dessa proteiner kan vara av betydelse. Det finns data på många andra
prover och tester på patienterna, som gör att man kan hitta något
oväntat som har ett samband Gas6 eller sAxl.

Första materialet som undersöktes var patienter med bråck på stora
kroppspulsådern. Patienter med stora bråck hade mer Gas6 och mindre
sAxl än friska frivilliga. Skillnaden är intressant, men räcker inte för
att diagnosticera, men visar att Gas6 och sAxl är förändrade i en
kärlsjukdom, vilket uppmuntrade oss till nya studier.

Andra materialet som undersöktes var patienter med en annan
kärlsjukdom, kritisk ischemi. Det är en sjukdom när blodcirkulationen
i fötterna är otillräcklig på grund av förträngningar i blodkärlen.
Smärta, långvariga sår och kallbrand kan bli följen. Gas6 och sAxl
var förhöjda i patienterna, och de som dog inom tre års uppföljning
hade förhöjda koncentrationer av både Gas6 och sAxl när provet togs,
detta oberoende av andra kända riskfaktorer.

Det tredje gruppen av patienter som undersöktes hade blodförgiftning.
Man har tidigare vetat att det ger förhöjda värden av Gas6, men ingen
har mätt sAxl i dessa patienter. Eftersom sAxl binder till och
inaktiverar Gas6 är det viktigt att veta om sAxl också ökar. Gas6 var
dubblerat, och sAxl ökade med tjugo procent, så det fanns mer fritt
Gas6. Gas6 var särskilt högt i de patienter som hade organsvikt och de
som behövde intensivvård.

Den fjärde gruppen var patienter med SLE, som är en sjukdom där
immunförsvaret skadar den egna kroppen av okända orsaker. sAxl och
Gas6 var förhöjda i patienter med aktiv sjukdom, och Gas6 och sAxl-koncentrationerna korrelerade med sjukdomsaktivitet, så att patienter med många symptom hade mer Gas6 och sAxl än patienter med få symptom.

Sammantaget har vi visat att Gas6 är bundet till sAxl i blodet, att Gas6 och sAxl är förhöjda i flera sjukdomar.
Acknowledgements

Björn! I am very grateful for the chance to do research in your lab. You know so much and is always available in moments of enthusiasm or grief. Sassan for cosupervising and encouraging. Coauthors Despina, Anders, Bengt, Adam, Per, Andreas, Gunnar och Anders for good cooperation, sharing those precious plasma samples and for help with the statistics and writing. People in the lab, past and present: Jonas, who taught me the good and bad sides of Gas6. Olof, that journal club on frogs and ultrasounds was highly remarkable. Anna G, for singing, dancing, acting and exaggerating. Sofia, for protein homology and the gradient of mess on our shared desk. Eva, for knowledge of New York City and platelets. Sara, for being a good catholic. Josefin, for making me run almost two marathons. Mike, for the baby immobilization device. Cecilia for sharing experience on dissertation matters and platelets, Sinh for comparisons of Milo and Tage. Li & Li-Jun for the name of Fugue, Eva-Lotta for encouraging my facial hairgrowth, Sunil for the indian love songs, Per for technical assistance and word puns, Lina for baby knowledge, Jun for dedicating months of purifying sMer, Danuta for RT-PCR insight, Helena for inheriting my stuff and continuing my research, or at least using my reagents. Ing-Marie, Astra and Ann-Louise for knowing how things are done and for help during my first steps in the lab. Anna B for showing me the almost magical ÄKTA machine and Lars for helping me in the grim world of tyrosine kinases. My former students, Elena, Wasen, Rickard and Kristina for making me think of what I am doing. All people on floor 4 and 5 for lunch room discussions, friendship and fun social events.
Mina föräldrar Eva & Göran för en bra uppväxt, fylld av ohämmad uppmuntran och fascination för hur saker fungerar. Mina syskon Erik, Josef & Maja, för gott samboskap under många år. Släkten med alla dess vindlingar för allt roligt den för med sig, den gamla som den nya ingifta. Alla vänner från när och fjärran, ni är väldigt bra att ha²⁴⁰, och hjälper mig hålla kontakten med den ganska märkliga världen utanför labbet.

Maja, for love, inspiration and cooperation when it comes to Tage.
References

46. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel


100. Mahajan NP, Earp HS. An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing


102. Goruppi S, Ruaro E, Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene. 1996;12:471-480.


pathway to protect oligodendrocytes from tumor necrosis factor 


112. Valverde P, Obin MS, Taylor A. Role of Gas6/Axl 
signaling in lens epithelial cell proliferation and survival. Exp 

113. Funakoshi H, Yonemasu T, Nakano T, Matumoto K, 
Nakamura T. Identification of Gas6, a putative ligand for Sky 
and Axl receptor tyrosine kinases, as a novel neurotrophic factor 

cortical neurons from amyloid beta protein-induced apoptosis. 

115. Couchie D, Lafdir F, Martin-Garcia N, Laperche Y, 
Zafrou N, Mavier P. Expression and role of Gas6 protein and 
of its receptor Axl in hepatic regeneration from oval cells in the 

116. Lafdir F, Chobert MN, Couchie D, et al. Induction of 
Gas6 protein in CCL4-induced rat liver injury and anti-apoptotic 
effect on hepatic stellate cells. Hepatology. 2006;44:228-239.

117. Lafdir F, Chobert MN, Deveaux V, et al. Growth arrest-
specific protein 6 deficiency impairs liver tissue repair after 

118. Dirks W, Rome D, Ringel F, Jager K, MacLeod RA, 
Drexler HG. Expression of the growth arrest-specific gene 6 
(GAS6) in leukemia and lymphoma cell lines. Leuk Res. 

119. Ito M, Nakashima M, Nakayama T, et al. Expression of 
receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in 
pediatric thyroid carcinomas around chernobyl. Thyroid. 

receptor tyrosine kinase in human thyroid carcinoma. Thyroid. 

121. Sun WS, Fujimoto J, Tamaya T. Clinical implications of 
coexpression of growth arrest-specific gene 6 and receptor


144. Keating AK, Kim GK, Jones AE, et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther. 2010;9:1298-1307.


159. Hall MO, Obin MS, Prieto AL, Burgess BL, Abrams TA. Gas6 binding to photoreceptor outer segments requires gamma-carboxyglutamic acid (Gla) and Ca(2+) and is required for OS phagocytosis by RPE cells in vitro. Exp Eye Res. 2002;75:391-400.


232. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of


